Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580

Patrick A. Eyers, Paul Van Den Ijssel, Roy A. Quinlan, Michel Goedert, Philip Cohen (Lead / Corresponding author)

    Research output: Contribution to journalArticle

    94 Citations (Scopus)

    Abstract

    Stress-activated protein kinase 2a, also called p38, is inhibited by SB 203580 and this drug has been used widely to implicate this enzyme in the regulation of many physiological processes. Here, we introduce a novel method of general application, which can be used to establish whether the effects of SB 203580 are mediated via inhibition of stress-activated protein kinase 2a/p38 or whether they result from 'non-specific' effects. Four events thought to occur upon activation of stress-activated protein kinase 2a/p38 have been established unequivocally. These are the activation of mitogen-activated protein kinase-activated protein kinase-2 and mitogen- and stress-activated protein kinase-1 and the phosphorylation of their presumed substrates, heat shock protein 27 and the transcription factor cyclic AMP response element binding protein, respectively. In contrast, the SB 203580-induced activation of c-Raf is independent of stress-activated protein kinase 2a/p38 inhibition. Copyright (C) 1999 Federation of European Biochemical Societies.

    Original languageEnglish
    Pages (from-to)191-196
    Number of pages6
    JournalFEBS Letters
    Volume451
    Issue number2
    DOIs
    Publication statusPublished - 21 May 1999

    Fingerprint

    Mitogen-Activated Protein Kinase 14
    Chemical activation
    Pharmaceutical Preparations
    HSP27 Heat-Shock Proteins
    Physiological Phenomena
    Cyclic AMP Response Element-Binding Protein
    Phosphorylation
    Mitogen-Activated Protein Kinases
    Protein Kinases
    Transcription Factors
    Proteins
    SB 203580
    Substrates
    Enzymes

    Keywords

    • CREB
    • MAPKAP-K2
    • MSK1
    • p38
    • SAPK2
    • SB203580

    Cite this

    Eyers, Patrick A. ; Van Den Ijssel, Paul ; Quinlan, Roy A. ; Goedert, Michel ; Cohen, Philip. / Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580. In: FEBS Letters. 1999 ; Vol. 451, No. 2. pp. 191-196.
    @article{3eb4bd05498f420d9481d5f2cca82e55,
    title = "Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580",
    abstract = "Stress-activated protein kinase 2a, also called p38, is inhibited by SB 203580 and this drug has been used widely to implicate this enzyme in the regulation of many physiological processes. Here, we introduce a novel method of general application, which can be used to establish whether the effects of SB 203580 are mediated via inhibition of stress-activated protein kinase 2a/p38 or whether they result from 'non-specific' effects. Four events thought to occur upon activation of stress-activated protein kinase 2a/p38 have been established unequivocally. These are the activation of mitogen-activated protein kinase-activated protein kinase-2 and mitogen- and stress-activated protein kinase-1 and the phosphorylation of their presumed substrates, heat shock protein 27 and the transcription factor cyclic AMP response element binding protein, respectively. In contrast, the SB 203580-induced activation of c-Raf is independent of stress-activated protein kinase 2a/p38 inhibition. Copyright (C) 1999 Federation of European Biochemical Societies.",
    keywords = "CREB, MAPKAP-K2, MSK1, p38, SAPK2, SB203580",
    author = "Eyers, {Patrick A.} and {Van Den Ijssel}, Paul and Quinlan, {Roy A.} and Michel Goedert and Philip Cohen",
    year = "1999",
    month = "5",
    day = "21",
    doi = "10.1016/S0014-5793(99)00552-9",
    language = "English",
    volume = "451",
    pages = "191--196",
    journal = "FEBS Letters",
    issn = "0014-5793",
    publisher = "Wiley",
    number = "2",

    }

    Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580. / Eyers, Patrick A.; Van Den Ijssel, Paul; Quinlan, Roy A.; Goedert, Michel; Cohen, Philip (Lead / Corresponding author).

    In: FEBS Letters, Vol. 451, No. 2, 21.05.1999, p. 191-196.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580

    AU - Eyers, Patrick A.

    AU - Van Den Ijssel, Paul

    AU - Quinlan, Roy A.

    AU - Goedert, Michel

    AU - Cohen, Philip

    PY - 1999/5/21

    Y1 - 1999/5/21

    N2 - Stress-activated protein kinase 2a, also called p38, is inhibited by SB 203580 and this drug has been used widely to implicate this enzyme in the regulation of many physiological processes. Here, we introduce a novel method of general application, which can be used to establish whether the effects of SB 203580 are mediated via inhibition of stress-activated protein kinase 2a/p38 or whether they result from 'non-specific' effects. Four events thought to occur upon activation of stress-activated protein kinase 2a/p38 have been established unequivocally. These are the activation of mitogen-activated protein kinase-activated protein kinase-2 and mitogen- and stress-activated protein kinase-1 and the phosphorylation of their presumed substrates, heat shock protein 27 and the transcription factor cyclic AMP response element binding protein, respectively. In contrast, the SB 203580-induced activation of c-Raf is independent of stress-activated protein kinase 2a/p38 inhibition. Copyright (C) 1999 Federation of European Biochemical Societies.

    AB - Stress-activated protein kinase 2a, also called p38, is inhibited by SB 203580 and this drug has been used widely to implicate this enzyme in the regulation of many physiological processes. Here, we introduce a novel method of general application, which can be used to establish whether the effects of SB 203580 are mediated via inhibition of stress-activated protein kinase 2a/p38 or whether they result from 'non-specific' effects. Four events thought to occur upon activation of stress-activated protein kinase 2a/p38 have been established unequivocally. These are the activation of mitogen-activated protein kinase-activated protein kinase-2 and mitogen- and stress-activated protein kinase-1 and the phosphorylation of their presumed substrates, heat shock protein 27 and the transcription factor cyclic AMP response element binding protein, respectively. In contrast, the SB 203580-induced activation of c-Raf is independent of stress-activated protein kinase 2a/p38 inhibition. Copyright (C) 1999 Federation of European Biochemical Societies.

    KW - CREB

    KW - MAPKAP-K2

    KW - MSK1

    KW - p38

    KW - SAPK2

    KW - SB203580

    UR - http://www.scopus.com/inward/record.url?scp=0032901378&partnerID=8YFLogxK

    U2 - 10.1016/S0014-5793(99)00552-9

    DO - 10.1016/S0014-5793(99)00552-9

    M3 - Article

    VL - 451

    SP - 191

    EP - 196

    JO - FEBS Letters

    JF - FEBS Letters

    SN - 0014-5793

    IS - 2

    ER -